Axovant Sciences Announces Changes to Management Team and Board of Directors
David Hungresigns as CEO and continues as scientific advisor to Roivant family of companies
- Dr. Pavan Cheruvu appointed as CEO of Axovant
Roger Jeffs, former President and co-CEO of United Therapeutics, and George Bickerstaff, former CFO of Novartis Pharma, join board of directors
- Conference call today at
8:00 a.m. EST
Pavan Cheruvu, M.D., has joined Axovant as Chief Executive Officer.
“I have appreciated the opportunity to lead Axovant and have enjoyed working with the teams at both Roivant and Axovant,” said Dr. Hung. “I hope to continue to assist these teams as a scientific advisor to the Roivant family of companies.”
“I would like to thank David for his commitment to Axovant over the past ten months, and we wish him well in his future endeavors,” said
“I am excited for the opportunity to lead Axovant, and I look forward to getting started,” said Dr. Cheruvu. “Our top priorities are to expand the pipeline with high-quality product candidates, solidify next steps for nelotanserin and RVT-104, and ensure operational excellence across all areas of the business. We will provide a comprehensive update on the company’s strategy by mid-year. Given Axovant’s strong cash position, we are starting from a solid foundation from which to rebuild the company’s value.”
Dr. Pavan Cheruvu has held roles of increasing responsibility at Roivant and supporting Axovant since 2015 and was appointed to the Roivant executive leadership team in 2017. A board-certified physician, Dr. Cheruvu completed his residency in internal medicine at
To participate in the live conference call today,
The live call is being webcast and can be accessed on the “Events and Presentations” page of the “Investors” section of the Company’s website at http://investors.axovant.com. A replay of the webcast will be available for 30 days following the live event.
About Axovant Sciences
Axovant is a clinical-stage biopharmaceutical company dedicated to advancing treatments for patients with life-altering neurologic conditions. Axovant is committed to developing a pipeline of product candidates, and ultimately commercializing them, by identifying and developing novel treatments for unmet needs in neurology. For more information, visit www.axovant.com.
This press release contains forward-looking statements, including statements regarding Axovant’s plans to expand its pipeline and solidify and pursue its future strategy. Forward-looking statements can be identified by the words “believe,” “anticipate,” “continue,” “estimate,” “project,” “expect,” “plan,” “potential,” “intends,” “will,” “would,” “could,” “should” or the negative or plural of these words or other similar expressions that are predictions or indicate future events, trends or prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the ability to identify and in-license or acquire product candidates, success, cost and timing of Axovant’s product development activities and clinical trials, increased regulatory requirements, and the risk that interim results or other preliminary analyses do not ensure that later or final results in a clinical trial or in related or similar clinical trials will replicate those interim results. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Axovant’s business in general, see the “Risk Factors” section of Axovant’s Quarterly Report on Form 10-Q filed with the
Chief Financial Officer
Source: Axovant Sciences Ltd.